Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

664
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
664
Dysrhythmias III: Characteristics of Dysrhythmias01:29

Dysrhythmias III: Characteristics of Dysrhythmias

571
Dysrhythmias, also known as arrhythmias, are irregular heart rhythms that result from abnormal electrical activity in the heart, affecting its ability to circulate blood efficiently. Tachyarrhythmias, a subset of dysrhythmias, are characterized by abnormally fast heart rates exceeding 100 beats per minute. Here are some types of tachyarrhythmias with their distinct ECG features:Sinus Tachycardia:Sinus tachycardia presents a regular heart rhythm with an increased rate of 101-180 beats per...
571
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

696
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
696
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

697
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
697
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

3.3K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereoretentive Norrish-Yang Photocyclization Mediated by Hydrogen Bonding.

Journal of the American Chemical Society·2026
Same author

Tracing the pathogenic PLN p.(Arg14del) variant across the globe; more than just a local curiosity.

Journal of cardiovascular translational research·2026
Same author

Physical activity and Brugada ECG pattern during 12-lead Holter monitoring.

The Journal of sports medicine and physical fitness·2026
Same author

Catalytic Enantioselective Multicomponent Reactions of Sulfoxonium Ylides Enabled by a Formal Rearrangement-A Versatile Entry to Enantioenriched α-Sulfanyl Carbonyl Compounds.

Angewandte Chemie (International ed. in English)·2026
Same author

Ensemble Analyzer: An Open-Source Python Framework for Automated Conformer Ensemble Refinement.

Journal of chemical information and modeling·2026
Same author

Inflammatory Hot Phases and Disease Trajectory in Desmosomal Cardiomyopathies.

Circulation·2026

Related Experiment Video

Updated: Feb 25, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K

Short QT Syndromes.

Fiorenzo Gaita1, Carla Giustetto1, Andrea Mazzanti1

  • 1Cardiology Department, Division of Cardiology, Cardinal Massaia Hospital, C.so Dante, 202, Asti 14100, Italy; Division of Cardiology, University of Turin, San Giovanni Battista Hospital, C.so Bramante, 88/90, Turin 10126, Italy.

Cardiac Electrophysiology Clinics
|August 4, 2017
PubMed
Summary

Short QT syndrome (SQTS) is a genetic heart disorder causing dangerous arrhythmias and sudden death. Current treatment involves defibrillator implantation, but hydroquinidine may help in specific patient groups.

More Related Videos

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.4K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

Related Experiment Videos

Last Updated: Feb 25, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K
Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.4K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

Area of Science:

  • Cardiology
  • Genetics
  • Electrophysiology

Background:

  • Short QT syndrome (SQTS) is a rare genetic disorder.
  • It is characterized by abbreviated QT intervals on electrocardiograms.
  • SQTS significantly increases the risk of sudden cardiac death and atrial fibrillation.

Purpose of the Study:

  • To review the genetic basis of Short QT syndrome.
  • To discuss current and potential therapeutic strategies for SQTS management.

Main Methods:

  • Literature review of genetic mutations associated with SQTS.
  • Analysis of clinical manifestations and current treatment guidelines.

Main Results:

  • Identified gain-of-function mutations in potassium channel genes (KCNH2, KCNQ1, KCNJ2) and loss-of-function mutations in the L-type calcium channel genes (CACNA1C, CACNB2).
  • Implantable cardioverter-defibrillator (ICD) is the primary therapy.
  • Hydroquinidine shows promise for pharmacologic management in children and asymptomatic elderly patients.

Conclusions:

  • Genetic mutations in ion channels are the primary cause of SQTS.
  • ICD implantation remains the gold standard for high-risk patients.
  • Pharmacologic therapy with hydroquinidine offers a potential alternative for specific populations.